Bisphosphonates are a class of drugs that slow the breakdown of bone, making them the most widely prescribed treatment for osteoporosis and several other conditions marked by excessive bone loss. They work by binding to bone mineral and suppressing the cells responsible for dissolving old bone tissue. First used clinically in the late 1960s for Paget’s disease, they have since become a cornerstone of fracture prevention, with a meta-analysis showing they reduce the overall risk of osteoporotic fractures by roughly a third.
How Bisphosphonates Work
Your skeleton is not a static scaffold. Bone constantly remodels itself through a cycle of breakdown and rebuilding. Specialized cells called osteoclasts dissolve small patches of old bone, and osteoblasts fill those patches with new bone. In conditions like osteoporosis, osteoclasts outpace osteoblasts, and net bone mass declines. Bisphosphonates interrupt this imbalance by targeting osteoclasts.
The drugs have a chemical backbone built around two phosphorus-containing groups, which gives them an unusually strong attraction to the calcium-rich mineral surface of bone. Once a bisphosphonate molecule latches onto bone, it sits there until an osteoclast comes along and begins dissolving that patch of mineral. The osteoclast absorbs the drug in the process, which either poisons it outright or disrupts internal signaling pathways the cell needs to function. The net result is fewer active osteoclasts and slower bone loss.
Not all bisphosphonates disable osteoclasts the same way. The newer, nitrogen-containing versions (alendronate, risedronate, ibandronate, zoledronate) block a specific enzyme inside the osteoclast, making them substantially more potent than the older, non-nitrogen versions like etidronate and clodronate, which work through a cruder mechanism that leads to toxic buildup inside the cell.
The Major Types and How They Are Given
In clinical practice, bisphosphonates split into two broad categories: oral tablets and intravenous infusions. The choice depends on the condition being treated, the patient’s tolerance, and sometimes kidney function.
- Alendronate: The most commonly prescribed oral bisphosphonate, typically taken as a weekly pill. Used primarily for postmenopausal osteoporosis and glucocorticoid-induced bone loss.
- Risedronate: Another oral option, available as a daily, weekly, or monthly pill. Similar fracture-prevention profile to alendronate, with evidence of vertebral and nonvertebral fracture reduction.
- Ibandronate: Available as a monthly oral tablet or a quarterly intravenous injection. Its fracture-reduction evidence is strongest at the spine; hip fracture data are less robust than for alendronate or risedronate.
- Zoledronate (zoledronic acid): Given as a once-yearly intravenous infusion for osteoporosis, or more frequently in cancer settings. The most potent bisphosphonate in widespread use, with evidence of fracture reduction at the spine, hip, and other sites.
In randomized trials, alendronate, risedronate, and zoledronate have all demonstrated the ability to reduce vertebral, nonvertebral, and hip fractures. Ibandronate’s track record is more limited, with strong evidence at the spine but less convincing data elsewhere.
The Absorption Problem With Oral Bisphosphonates
One of the most distinctive things about taking an oral bisphosphonate is the strict dosing ritual. The drugs are absorbed extremely poorly from the gut. Bioavailability ranges from roughly 0.6% to 3%, meaning the vast majority of each pill passes through without entering the bloodstream.
The reason is chemical: the phosphate groups that allow the drug to grip bone also make it highly water-soluble and electrically charged, which prevents it from crossing the fatty membranes lining the intestine. Food and most beverages make absorption even worse by forming complexes with the drug that the gut cannot take up at all. For this reason, oral bisphosphonates must be swallowed first thing in the morning on a completely empty stomach, with a full glass of plain water, and you need to wait anywhere from 30 minutes to two hours (depending on the specific drug) before eating or drinking anything else.
That fasting window is not optional. Skipping it does not just reduce the dose a little; it can essentially eliminate it. The strict protocol is also one of the main reasons people stop taking these drugs, which has led to ongoing research into formulations that might relax the fasting requirement.
Fracture Prevention in Osteoporosis
Fracture prevention is the primary reason bisphosphonates exist in modern medicine. A meta-analysis pooling data from multiple randomized trials found that bisphosphonate use was associated with a roughly 38% reduction in overall osteoporotic fracture risk, with a 45% reduction in vertebral fractures and a 27% reduction in nonvertebral fractures.
These benefits do not appear overnight. A separate meta-analysis focused on timing found that, on average, about 12 months of bisphosphonate therapy were needed to prevent one nonvertebral fracture per 100 postmenopausal women treated. To prevent one hip fracture, roughly 200 women would need to be treated for about 20 months. For clinical vertebral fractures, the time-to-benefit was about 12 months for every 200 women treated.
These numbers matter because they help set realistic expectations. If you are starting a bisphosphonate for osteoporosis, the payoff is cumulative over the first one to two years. This is part of why adherence is so important and why short courses are generally not recommended for people at high fracture risk.
Beyond Osteoporosis
Bisphosphonates are used across several conditions where bone is being destroyed faster than it should be.
Paget’s Disease
Paget’s disease was actually the first condition ever treated with a bisphosphonate, back in the late 1960s when etidronate was found to suppress the disease’s abnormally high bone turnover. Today, bisphosphonates remain the treatment of choice for Paget’s disease. Zoledronic acid, given as a single intravenous infusion, has shown the ability to maintain normal markers of bone turnover for extended periods, whereas risedronate showed a gradual increase in those markers over time after treatment.
Cancer-Related Bone Disease
When cancers such as breast, prostate, or lung cancer spread to bone, bisphosphonates help reduce skeletal complications like pathological fractures, spinal cord compression, and the need for radiation to bone. Zoledronic acid is the most commonly used bisphosphonate in this setting. In a trial of patients with bone metastases from lung cancer and other solid tumors, a 4 mg dose of zoledronic acid increased the median time to the first skeletal event from 163 days with placebo to 230 days, and reduced the overall risk of skeletal events by about 27%.
Bisphosphonates are also used to treat hypercalcemia of malignancy, a dangerous spike in blood calcium that occurs when tumors release calcium from bone or produce hormones that drive calcium levels up. Intravenous zoledronic acid has proven more effective than older agents at normalizing calcium in severe cases.
Glucocorticoid-Induced Osteoporosis
Long-term use of corticosteroids like prednisone causes significant bone loss, often faster than typical age-related osteoporosis. Oral bisphosphonates are considered first-line treatment for this problem, largely because they are effective and inexpensive. Alendronate, risedronate, and zoledronate all prevent bone loss at the spine and hip in people starting corticosteroids, and increase bone density in people already on long-term steroid therapy. Pooled data from two risedronate trials showed that fractures occurred in about 5% of treated patients compared with 16% on placebo during the first year. When bisphosphonate therapy is started within 90 days of beginning chronic corticosteroid use, fracture reduction may reach about 48%.
Osteogenesis Imperfecta in Children
Bisphosphonates are one of the few treatments used in children with osteogenesis imperfecta, the genetic “brittle bone” condition. Cyclic intravenous pamidronate has been shown to increase bone density and decrease fracture rates in these patients. Oral risedronate has also demonstrated benefit, increasing bone density and reducing the risk of both first and recurrent clinical fractures in children with osteogenesis imperfecta, while being generally well tolerated.
Gastrointestinal Side Effects
The most common complaint with oral bisphosphonates involves the upper digestive tract. Because the drugs can irritate the lining of the esophagus and stomach on direct contact, they sometimes cause heartburn, nausea, or abdominal discomfort. The damage is not subtle under a scope: endoscopic studies have found esophageal erosions in about 10% of bisphosphonate users and stomach or duodenal ulcers in roughly 4%.
Early reports of esophagitis with alendronate found that the risk was strongly tied to how the pill was taken. Swallowing it with little or no water, lying down during or after taking the tablet, and continuing to take the drug after symptoms had already started were all associated with esophageal injury. People with pre-existing esophageal conditions were also at higher risk. These findings are exactly why the dosing instructions emphasize sitting or standing upright for at least 30 minutes after taking the pill and drinking a full glass of water with it.
If upper GI side effects are intolerable, switching to an intravenous bisphosphonate bypasses the esophagus and stomach entirely, which eliminates this particular problem.
The Flu-Like Reaction After Intravenous Infusion
Intravenous bisphosphonates, especially zoledronic acid, commonly trigger what is called an acute phase reaction within the first day or two after infusion. Symptoms include fever, muscle aches, headache, and fatigue. The reaction is driven by a temporary spike in inflammatory signaling molecules, which tend to peak around 24 hours and settle back toward normal within about three days.
This reaction is most pronounced after the very first infusion and tends to be milder or absent with subsequent annual doses. Over-the-counter pain relievers like acetaminophen can help manage symptoms. While it feels unpleasant, the reaction is self-limiting and does not indicate a serious adverse event.
Osteonecrosis of the Jaw
One of the most feared complications associated with bisphosphonates is osteonecrosis of the jaw, a condition where a patch of jawbone loses its blood supply and dies, often leaving exposed bone in the mouth that fails to heal. The risk is heavily dose-dependent. In a large case-control study, intravenous bisphosphonate use carried a dramatically higher association with jaw osteonecrosis than oral use. Among cancer patients receiving frequent intravenous zoledronate infusions, crude incidence rates ranged from about 3% to 8.5% depending on cancer type.
For people taking oral bisphosphonates for osteoporosis, the risk is far lower but not zero. In the case-control study that included non-cancer patients, oral bisphosphonate use still carried a meaningful association with jaw osteonecrosis, and the risk climbed after two or more years of treatment. Dental extractions were a major trigger, with the odds of developing the condition increasing roughly sixfold around the time of a tooth extraction. Denture use also doubled the risk in cancer patients receiving bisphosphonates.
Because of this connection, dentists and physicians generally recommend a thorough dental evaluation before starting bisphosphonate therapy, and any necessary invasive dental work should ideally be completed beforehand. If you are already on a bisphosphonate and need a tooth pulled, your prescriber and dentist should coordinate the timing.
Atypical Femur Fractures
A paradox emerged in the mid-2000s: a drug designed to prevent fractures appeared to be causing an unusual type of fracture. Atypical femur fractures occur along the shaft of the thighbone rather than at the hip, often with minimal trauma, and have distinctive features on X-ray. Public concern about these fractures contributed to a dramatic drop (over 50%) in bisphosphonate prescriptions.
The relationship between long-term bisphosphonate use and these fractures is supported by case series and some epidemiological studies, though the evidence base is mixed, with several population-level analyses failing to confirm the association. What is generally agreed on is that the risk is extremely rare in absolute terms. For every atypical femur fracture that occurs, bisphosphonates are estimated to prevent more than 1,200 typical osteoporotic fractures, including over 130 hip fractures. The risk rises with duration of use, which is one of the main reasons drug holidays are recommended after several years of continuous therapy.
Drug Holidays
Bisphosphonates have an unusual property that sets them apart from most medications: once embedded in bone, they stay there for years. The skeletal half-life of alendronate has been estimated at roughly 11 years, reflecting how slowly bone turns over and releases stored drug. This means that even after you stop taking the medication, it continues working to some degree as old bone is gradually remodeled.
This residual effect is the basis for the concept of a “drug holiday.” After three to five years of oral bisphosphonate therapy (or three years of annual intravenous zoledronate), guidelines suggest considering a temporary pause. The rationale is straightforward: fracture protection persists for some time after stopping, while the risk of rare complications like atypical femur fractures and jaw osteonecrosis appears to decline once the drug is discontinued. A holiday of two to three years is commonly recommended for most patients after long-term therapy, though the optimal duration remains a matter of clinical judgment.
Not everyone is a candidate for a drug holiday. People at very high fracture risk, such as those with very low bone density scores, prior vertebral fractures, or ongoing corticosteroid use, may need continuous treatment. The decision involves weighing the small but real risk of rare complications against the potentially greater risk of a fragility fracture.
Kidney Considerations
Because bisphosphonates are cleared through the kidneys, renal function matters. Most prescribing guidelines set a cutoff below which bisphosphonates are either avoided or used with extra caution. A study of older osteoporotic patients found that while overall kidney function trajectories did not significantly differ between those with very low and moderately reduced kidney function during 12 months of bisphosphonate therapy, the group with the lowest kidney function had a substantially higher risk of renal-related adverse events. At six months, about 13% of patients with very low kidney clearance experienced a renal side effect, compared with about 2% of those with better kidney function.
For intravenous zoledronate specifically, adequate hydration before and during the infusion is important, and the drug is typically not given if kidney function falls below a certain threshold. Your prescriber should check kidney function with a blood test before starting any bisphosphonate and monitor it periodically, especially if you have existing kidney problems.
Vitamin D and Calcium Before Starting Treatment
Because bisphosphonates slow the release of calcium from bone, they can occasionally tip the balance toward low blood calcium, especially in people who are already deficient in vitamin D. Severe vitamin D deficiency (blood levels below about 25 nmol/L) should be corrected before starting a potent bisphosphonate to avoid symptomatic drops in calcium, which can cause muscle cramps, tingling, or in extreme cases, dangerous heart rhythm problems. Most prescribers will check your vitamin D level beforehand and recommend supplementation if needed. Routine calcium and vitamin D supplements are typically continued alongside bisphosphonate therapy to support the bone-building side of the equation.
How Bisphosphonates Compare to Newer Alternatives
Bisphosphonates are no longer the only option for treating osteoporosis, and the newer drugs work through entirely different mechanisms. Denosumab is an injectable antibody given every six months that blocks a signaling molecule osteoclasts need to develop. Teriparatide is a daily injection of a fragment of parathyroid hormone that actually stimulates bone formation rather than just slowing breakdown.
In head-to-head comparisons, denosumab tends to produce greater gains in bone density than bisphosphonates, owing to its more complete suppression of bone resorption. A meta-analysis found that both teriparatide and denosumab were more effective than alendronate and risedronate at reducing vertebral fractures. For nonvertebral and hip fractures, the differences were less dramatic: denosumab, alendronate, and risedronate all significantly reduced hip fracture risk compared to placebo, with broadly similar effect sizes.
When patients switch from long-term bisphosphonates to teriparatide, there can be a transient dip in hip bone density during the first year, though spine density tends to increase. Switching to denosumab avoids that dip and generally maintains or builds on the gains achieved with bisphosphonates.
Despite the newer options, bisphosphonates remain the default first-line treatment for most patients with osteoporosis. They have decades of safety data, they are available as inexpensive generics, and their long skeletal half-life means benefits persist even after discontinuation. Denosumab and teriparatide are typically reserved for people who cannot tolerate bisphosphonates, have very high fracture risk, or have not responded adequately to initial therapy.
An Unlikely Origin Story
Bisphosphonates were not originally designed as medicines. The compounds have been known since the 1800s and were used industrially as water softeners and scale inhibitors in pipes and boilers. Their chemical structure allows them to bind tightly to calcium-containing minerals, which is exactly the property that made them useful for preventing calcium buildup in industrial water systems. Researchers noticed this same affinity applied to the calcium phosphate crystals in bone, which led to the first animal experiments in the 1960s showing that bisphosphonates could block both mineralization and bone destruction. The leap from water-treatment chemical to blockbuster osteoporosis drug took decades of refinement, but the core chemistry has remained remarkably consistent.